ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,872.16
-2.95%
US Tech 100
20,658.80
0.00%
다우존스 지수
42,326.87
-2.58%
Bitcoin
101,400.02
1.33%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. BioCryst Pharmaceuticals Inc (BCRX)

  7. BioCryst Pharmaceuticals Inc (BCRX) 뉴스

BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc (BCRX)

NASDAQ
7.31
0.00
(0.00%)
마감 19 12월 6:00AM
15분 지연
0.00
0.00
(0.00%)
시간외 거래: -
15분 지연

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

프리미엄

BCRX 뉴스

공식 뉴스 전용

Form 8-K - Current report
Edgar (US Regulatory)
02 10월 2024
BCRX (0.00%)

Form 8-K - Current report
Edgar (US Regulatory)
30 9월 2024
BCRX (0.00%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
04 9월 2024
BCRX (0.00%)

BCRX Discussion

게시물 보기
Monksdream Monksdream 2 월 전
BCRX under $10

👍️0
Monksdream Monksdream 5 월 전
BCRX under $8
👍️0
Monksdream Monksdream 8 월 전
BCRX new 52 week low
👍️0
Monksdream Monksdream 8 월 전
BCRX new 52 lo
👍️0
Monksdream Monksdream 8 월 전
BCRX new 52 week lo
👍️0
Monksdream Monksdream 9 월 전
BCRX under $10
👍️0
Monksdream Monksdream 10 월 전
BCRX 10Q 2/26
👍️0
Calcumad Calcumad 11 월 전
It is turning around. Just let the big guys manipulate it enough so they can collect from the shorting and then buy cheaper
👍️0
james kent james kent 1 년 전
when will it turn around?
👍️0
james kent james kent 1 년 전
when will it turn around?
👍️0
ttubular ttubular 2 년 전
Huge buys in AH
👍️0
VivaLasVegas VivaLasVegas 2 년 전
Why is this symbol now taking a digger with all the rest?
What did Stoney do or not do?
👍️0
ttubular ttubular 2 년 전
6:58a ET 8/4/2022 - Globe Newswire
BioCryst Resumes Enrollment in BCX9930 Clinical Program
Mentioned: BCRX
EQNX::TICKER_START (NASDAQ:BCRX), EQNX::TICKER_END BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the U.S. Food and Drug Administration (FDA) has lifted its partial clinical hold on the BCX9930 program. The company will resume enrollment in global clinical trials under revised protocols at a reduced dose of 400 mg twice daily of BCX9930. This includes the REDEEM-1 and REDEEM-2 pivotal trials in patients with paroxysmal nocturnal hemoglobinuria (PNH) and the RENEW proof-of-concept trial in patients with C3 glomerulopathy (C3G), immunoglobulin A nephropathy (IgAN) and primary membranous nephropathy (PMN).

Clinical evidence and recent laboratory studies have informed the company's hypothesis that crystals form in the kidneys of some patients. The company believes that lowering the dose to 400 mg and ensuring adequate hydration will dilute the concentration of drug in the urine below the threshold where crystals can form.
👍️0
rosemountbomber rosemountbomber 3 년 전
Don’t have the link but apparently Denner sold a bunch of BCRX 05/16/2022.
👍️0
conix conix 3 년 전
BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded by stock analysts at Barclays from an “overweight” rating to an “equal weight” rating in a report released on Monday, The Fly reports. They presently have a $13.00 price target on the biotechnology company’s stock, down from their previous price target of $22.00. Barclays‘s price objective suggests a potential upside of 14.14% from the stock’s current price.

BCRX has been the subject of a number of other research reports. Piper Sandler restated an “in-line” rating and issued a $24.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, February 23rd. Evercore ISI lowered their target price on shares of BioCryst Pharmaceuticals from $25.00 to $15.00 in a research note on Friday, April 8th. StockNews.com assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Thursday, February 24th. Finally, Oppenheimer lowered their target price on shares of BioCryst Pharmaceuticals from $20.00 to $16.00 and set an “outperform” rating on the stock in a research note on Monday, April 11th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $19.09.
👍️0
Cosa Cosa 3 년 전
I guess it was perfect timing in a way...
👍️0
Cosa Cosa 3 년 전
I reduced my position here to buy more AUPH (facepalm)
👍️0
starkd748 starkd748 3 년 전
13.90s pullback yesss
👍️0
starkd748 starkd748 3 년 전
Overbought pullback in progress TA saves money
👍️0
Limey42 Limey42 3 년 전
You were saying? LMFAO!!!!!!!!
👍️0
game7alcs game7alcs 3 년 전
BCRX just on CNBC for large call volume action
👍️0
starkd748 starkd748 3 년 전
Burnt to a crisp rsi enjoy
👍️0
starkd748 starkd748 3 년 전
Lmfao the rsi is 100 pullback in progress
👍️0
ttubular ttubular 3 년 전
Understatement
👍️0
Limey42 Limey42 3 년 전
This company is a juggernaut!
👍️0
plexrec plexrec 3 년 전
Worldwide addressable market ??? Any estimate what kind of sales company is targeting ??? Totals ???? Rare diseases etc ????? TIA
👍️0
ezyE ezyE 3 년 전
Great buying opportunity.
Shouldn't be this low.
👍️0
easyrider1 easyrider1 3 년 전
What a complete manipulation to knock this down to get cheap stock. IMHO, the best low priced play in the market. The earnings report wil get this th $18 Total disregard for upgrades etc. this is a buying opportunity.
👍️0
easyrider1 easyrider1 3 년 전
Total joke to knock this down under $15 with all the positive news in the short term. Cashing in my soda bottles to buy more
👍️0
starkd748 starkd748 3 년 전
Might buy some options here
👍️0
easyrider1 easyrider1 3 년 전
Strongest day since the ill fated secondary announcement and we held most of the gains. Now we need volume.
👍️0
MZlu MZlu 3 년 전
I remember in recent weeks, we have seen some PR operations which I don't know if they were initiated by BioCryst:
- They won a prize for R&D
- They won a prize for marketing
- Barron's did a favorable mention of the Company
Looks like the big boys are shifting the narrative.
👍️0
easyrider1 easyrider1 3 년 전
First sign of life….someone realizes that this a buy
👍️0
Deano361 Deano361 3 년 전
Yeah been 18 months now and holding for me . I thin pnh results soon will help us
👍️0
easyrider1 easyrider1 3 년 전
I can’t believe that we are trending downward and broke $14. I keep buying a tad on each dip, but the dips are getting lower. I don’t understand what I’m missing with the breakout sales and potential for nearing profitability and real potential for a buyout.

This is still one of my favorite holdings but so disappointing since the Mgmt’s botched secondary attempt and lack of credible explanation.
👍️0
Deano361 Deano361 3 년 전
Yes two positive things going on . The new drug getting approvals and revenue and the pnh upcoming fast track trials
👍️0
Cosa Cosa 3 년 전
The sharp increase in revenue is what got my attention!
👍️0
Cosa Cosa 3 년 전
"Facepalm" I jinxed you guys.
👍️0
bhulkupk bhulkupk 3 년 전
Hi Cosa, welcome…
👍️0
Deano361 Deano361 3 년 전
Hi, been in since March/april 2020 from $3s. The key to this stock are upcoming 4Q results from PNH. PNH positive data makes this a $100 stock in 18 months IMO. Keep an eye on warrants and data.
👍️0
Cosa Cosa 3 년 전
Hello All, new here. Grabbed a little just to have in my portfolio to keep an eye on this. Looks like its been consolidating for almost 5 months! Still doing DD.
👍️0
easyrider1 easyrider1 3 년 전
Can’t believe with all the recent news especially appointment of Galson to the board and connections with Amgen that we’re not at $20 by now. The dip to the low $14’s was a gift.

More publications are suggesting that Bcrx is one off the best stock pics of the year. This is my favorite stock as I continue to accumulate…..doesn’t seem like there is anything but strong upside
👍️0
Deano361 Deano361 3 년 전
Well, it’s one of my few long 3 year stocks IMO . Started at $3 last year
👍️0
bhulkupk bhulkupk 3 년 전
Oh okay, so I can buy some for long term? Thanks in advance.
👍️0
Deano361 Deano361 3 년 전
It’s a quote from executive and it’s all about pnh for the future . Pnh is going to be Golden !!
👍️0
bhulkupk bhulkupk 3 년 전
How?
👍️0
Limey42 Limey42 3 년 전
Embarrassment of riches!
👍️0
MZlu MZlu 3 년 전
I think it is a public show of the poison pill clause. There may have been a potential buyer who wanted to play hard ball but got cock-blocked by Jon "Biochad" Stonehouse.
👍️0
easyrider1 easyrider1 3 년 전
Totally agree. No one saw secondary offering coming after upbeat ER. No one ever saw another offer being pulled. Company owes us a true explanation re timing and intent
👍️0
Limey42 Limey42 3 년 전
Some crazy shit Stoney pulled off today!!!
👍️0

최근 히스토리

NASDAQ
BCRX
BioCryst Pharmaceuticals
EU
BPCNW
BPCE 1.202% Coupon due 1...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유